R&D

TEDMED 2018

June 19, 2018

TEDMED is the health and medicine edition of the famous TED conference. Once a year, a select group of Delegates come together for 2 ½ days to experience 40+ remarkable speakers and 20 disruptive innovators as they transport all of us into a new world of possibilities for our health.

Kazia Releases Preliminary Cantrixil Phase I Data

June 19, 2018

SYDNEY, June 19, 2018 /PRNewswire/ — Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to provide an interim update to shareholders regarding its phase I clinical trial of Cantrixil (TRX-E-002-1) in relapsed or recurrent ovarian cancer. The phase I study of Cantrixil commenced in December 2016 at five centres […]

Kallyope and Novo Nordisk Announce Collaboration to Discover Novel Therapeutics for Obesity and Diabetes

June 19, 2018

NEW YORK, June 19, 2018 /PRNewswire/ — Kallyope Inc. and Novo Nordisk A/S today announced that they have entered into a research collaboration and option agreement to discover novel peptide therapeutics to treat obesity and diabetes. Kallyope will receive an upfront payment and research support for activities conducted in the collaboration. Under the terms of […]

Novus Therapeutics Receives FDA Guidance at Type C Meeting for OP-02 in the Treatment and Prevention of Otitis Media

June 19, 2018

IRVINE, Calif.–(BUSINESS WIRE)–Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), announced receipt of final meeting minutes from the U.S. Food and Drug Administration (FDA) following a Type C meeting held at the Company’s request to discuss its OP-02 development […]

Celyad Doses First AML Patient at Final Dose Level in CYAD-01 THINK Trial and Begins Dosing First Patient With Second Cycle of Therapy

June 19, 2018

MONT-SAINT-GUIBERT, Belgium, June 19, 2018 (GLOBE NEWSWIRE) — Celyad (Euronext Brussels:CYAD) (Euronext Paris:CYAD) (NASDAQ:CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell therapies, today announced the first Acute Myeloid Leukemia (AML) patient was dosed with the first injections at the third and final dose level of CYAD-01 in the hematological arm of […]

MediWound Expands Its NexoBrid® Phase 3 Children Innovation Debridement Study (CIDS) to the U.S.

June 19, 2018

YAVNE, Israel, June 19, 2018 (GLOBE NEWSWIRE) — MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced the expansion of its NexoBrid Phase 3 Children Innovation Debridement Study (CIDS) to United States burn centers, following approval of the study protocol by the […]

Leading BioSciences Reports Positive Interim Results from Phase 2 Trial of LB1148 in Patients Undergoing Major Surgery

June 19, 2018

CARLSBAD, Calif., June 19, 2018 (GLOBE NEWSWIRE) — Leading BioSciences, a drug development company focused on improving human health through therapeutic protection of the Gastrobiome™, today reported positive interim data from the company’s ongoing Phase 2 clinical trial of its lead drug candidate, LB1148, in patients undergoing major cardiovascular surgery. Results from the planned interim […]

Allena Pharmaceuticals Completes Animal Proof-of-Concept Study for ALLN-346, Lead Product Candidate for Hyperuricemia in the Setting of Advanced Chronic Kidney Disease

June 19, 2018

NEWTON, Mass., June 19, 2018 (GLOBE NEWSWIRE) — Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced the completion of an animal proof-of-concept study supporting the selection of ALLN-346 as its lead product candidate […]

CrownBio Enters Partnership with Pierre Fabre to Accelerate Discovery and Development of Immuno-Oncology Agents

June 19, 2018

SAN DIEGO, June 19, 2018 (GLOBE NEWSWIRE) — Crown Bioscience, a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, announces that it has been selected by Pierre Fabre Research Institute as one of their partners to advance their immuno-oncology drug discovery pipeline. CrownBio boasts […]

Fortress Biotech Announces Publication of Phase 1 Data on CNDO-109-Activated Allogeneic Natural Killer Cells in Acute Myeloid Leukemia in Biology of Blood and Marrow Transplantation

June 19, 2018

NEW YORK, June 19, 2018 (GLOBE NEWSWIRE) — Fortress Biotech (NASDAQ:FBIO) (“Fortress”), a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products, today announced that data from a Phase 1 clinical trial evaluating Fortress’ CNDO-109-activated allogeneic natural killer (NK) cells in acute myeloid leukemia (AML) patients have been published in the […]

Advancing Dronabinol Obstructive Sleep Apnea Program with Letter of Intent for Co-Development and Supply Agreement with Noramco, Inc.

June 19, 2018

Glen Rock, N.J., June 19, 2018 (GLOBE NEWSWIRE) — RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), is pleased to announce that on June 13, 2018, it entered into a letter of intent (“LOI”) with Noramco, Inc., pursuant to which the parties have entered into a ninety-day period during which they will negotiate a […]

SetPoint Medical Reports Positive Long-term Results from its Clinical Study of Bioelectronic Medicine to Treat Rheumatoid Arthritis

June 19, 2018

Valencia, CA – June 19, 2018 – SetPoint Medical, a clinical-stage biomedical technology company developing bioelectronic therapy for chronic inflammatory diseases, announced positive long-term data for its first-in-human study using bioelectronic medicine for rheumatoid arthritis (RA). Building on the positive 3-month results that were published in Proceedings of the National Academy of Sciences (PNAS) in […]

SAMDI Tech Inc. Awarded Phase I Small Business Innovation Research Grant From NIH

June 19, 2018

Chicago, June 19, 2018 (Business Wire) – SAMDI Tech Inc., the industry’s leading provider of label-free drug discovery solutions, is pleased to announce it has received a Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH) to develop the first cell-based and label-free, high-throughput assay of specific enzyme activities.   Funding […]

Elligo and Partners Participate in Federal Real-World Evidence Project

June 19, 2018

Austin, Texas, June 19, 2018 (Business Wire) — Elligo Health Research, which offers the only platform that brings clinical research direct to clinical health care, announces that Flatiron Health and the University of Chicago have agreed to act as data partners in a federal project led by the FDA to develop and pilot a common […]

Cerus Presents Results of European Phase 3 Chronic Anemia Study at the 23rd Congress of European Hematology Association

June 18, 2018

CONCORD, Calif.–(BUSINESS WIRE)–Cerus Corporation (Nasdaq: CERS) announced that results from SPARC, the Company’s European Phase 3 study evaluating the efficacy and safety of INTERCEPT-treated red blood cells (RBCs) in thalassemia major patients, were presented today at the 23rd Congress of European Hematology Association (EHA) in Stockholm Sweden in a poster presentation entitled, “A Randomized, Controlled, […]

Phase 3 QuANTUM-R Study Demonstrates Daiichi Sankyo’s Quizartinib Significantly Prolongs Overall Survival as Single Agent Compared to Chemotherapy in Patients with Relapsed/Refractory AML with FLT3-ITD Mutations

June 18, 2018

TOKOYO, MUNICH, and BASKING RIDGE, N.J., June 16, 2018 /PRNewswire/ — Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced that positive results from the pivotal QuANTUM-R phase 3 study of single agent quizartinib were presented today as a late-breaking oral presentation in the plenary program at the 23rd Congress of the European Hematology Association (EHA) […]

Aprea Therapeutics Presents Results From Phase Ib/II Clinical Study of APR-246 and Azacitidine (AZA) in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) at the 2018 European Hematology Association (EHA) Annual Meeting in Stockholm

June 18, 2018

BOSTON and STOCKHOLM, June 17, 2018 /PRNewswire/ — Aprea Therapeutics presented results at the 2018 EHA Annual Meeting from its Phase Ib/II clinical study in MDS. The ongoing study is evaluating the safety and efficacy of APR-246 in combination with azacitidine for the treatment of TP53 mutated MDS. The study is sponsored by the Moffitt […]

FEEDBACK